专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070104852A1 Casing-packed cooked rice and its production process 审中-公开
标题翻译：套装米饭及其生产工艺
公开(公告)号：US20070104852A1
公开(公告)日：2007-05-10
申请号：US10573315
申请日：2004-07-07
申请人： Youishi Terao , Tsuyoshi Yamagata
发明人： Youishi Terao , Tsuyoshi Yamagata
IPC分类号： A23L1/00
CPC分类号： A23L7/196 , A23L29/206 , A23L29/281
摘要： An object of the present invention is to provide: casing-packed cooked rice which has an excellent eating feel and an excellent flavor; and a production process which can mass-produce this casing-packed cooked rice. As a means of achieving this object, the casing-packed cooked rice according to the present invention is casing-packed cooked rice comprising an edible casing and a steam-cooked raw material for the cooked rice which material is packed in the edible casing, with the casing-packed cooked rice being characterized in that the raw material for the cooked rice contains a gelled material solidifiable when cold. The process according to the present invention for production of casing-packed cooked rice is a process comprising the steps of: packing a raw material for the cooked rice into an edible casing; and then steam-cooking the packed material; thereby obtaining the casing-packed cooked rice; with the process being characterized by further comprising the step of increasing the viscosity of the raw material for the cooked rice with a gelled material, solidifiable when cold, before the step of packing the raw material for the cooked rice.
摘要翻译：本发明的目的是提供一种具有优良的食用感和优良风味的包装米饭，以及可以大量生产这种包装的米饭的生产方法。作为实现该目的的手段，本发明的包装好的米饭是包装好的米饭，其中包括可食用的外壳和用于烹饪的米饭的蒸煮的原料，该材料被包装在可食用的外壳中，包装好的米饭的特征在于，米饭的原料含有在冷时可凝固的凝胶材料。根据本发明的用于生产包装米饭的方法是一种方法，包括以下步骤：将米饭的原料包装在可食用的外壳中; 然后对包装材料进行蒸汽蒸煮; 从而获得包装的米饭; 该方法的特征还在于，在用米饭的原料包装步骤之前，用胶凝材料提高米饭原料的粘度，在冷时可以固化的步骤。

2. 发明授权

US5726325A Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US5726325A
公开(公告)日：1998-03-10
申请号：US849399
申请日：1997-06-06
申请人： Makoto Yoshida , Shin-ichi Sasaki , Shigeru Aono , Shigeki Fujiwara , Haruki Takai , Tsuyoshi Yamagata , Ken Nagashima , Akira Karasawa
发明人： Makoto Yoshida , Shin-ichi Sasaki , Shigeru Aono , Shigeki Fujiwara , Haruki Takai , Tsuyoshi Yamagata , Ken Nagashima , Akira Karasawa
IPC分类号： C07C235/16 , C07D221/16 , C07D307/93 , C07D313/12 , C07D333/80 , C07D337/12 , C07D491/04 , C07D491/044 , C07D493/04 , C07D495/04 , C07D313/02
CPC分类号： C07D491/04 , C07C235/16 , C07D221/16 , C07D307/93 , C07D313/12 , C07D333/80 , C07D337/12 , C07D493/04 , C07D495/04 , C07C2103/16 , C07C2103/18 , C07C2103/32
摘要： The present invention relates to tricyclic compounds represented by general formula (I) which are useful as therapeutic agents for urinary incontinence: ##STR1## wherein R.sup.1 represents hydrogen and the like; --X.sup.1 --X.sup.2 --X.sup.3 -- represents --CR.sup.2 .dbd.CR.sup.3 --CR.sup.4 .dbd.CR.sup.5 -- (wherein R.sup.2, R.sup.3, R.sup.4, and R.sup.5 represent hydrogen and the like) and the like; and Y represents --CH.sub.2 O-- and the like.
摘要翻译： PCT No.PCT / JP96 / 02997 Sec。 371日期：1997年6月6日 102（e）日期1996年6月6日PCT PCT 1996年10月16日PCT公布。公开号WO97 / 14672 日期：1997年04月24日本发明涉及可用作尿失禁治疗剂的通式（I）表示的三环化合物：其中R1表示氢等; -X1-X2-X3-表示-CR2 = CR3-CR4 = CR5-（其中R2，R3，R4和R5表示氢等）等; Y表示-CH 2 O-等。

3. 发明授权

US07122173B2 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia 失效
公开(公告)号：US07122173B2
公开(公告)日：2006-10-17
申请号：US10473348
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William C. de Groat , Naoki Yoshimura , Adrian Sculptoreanu
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William C. de Groat , Naoki Yoshimura , Adrian Sculptoreanu
IPC分类号： A61K10/00 , A61K49/00
CPC分类号： A61K31/55 , A61K31/38 , A61K31/44
摘要： The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.

4. 发明申请

US20060160887A1 Medicinal composition 审中-公开
标题翻译：药用成分
公开(公告)号：US20060160887A1
公开(公告)日：2006-07-20
申请号：US10562635
申请日：2004-07-16
申请人： Tsuyoshi Yamagata , Shiro Shirakura
发明人： Tsuyoshi Yamagata , Shiro Shirakura
IPC分类号： A61K31/381
CPC分类号： C07D495/04 , A61K31/137 , A61K31/216 , A61K31/38 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical composition which is useful in the treatment for overactive bladder and the like, and comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-d ihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof, and an anticholinergic agent.
摘要翻译：本发明提供一种药物组合物，其可用于治疗膀胱过度活动症等，并且包含3,3,3-三氟-2-羟基-2-甲基-N-（5,5,10-三氧代-4 ，10-二氢噻吩并[3,2-c] [1]苯并硫代-9-基）丙酰胺或其药学上可接受的盐，和抗胆碱剂。

5. 发明申请

US20100267796A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME 审中-公开
标题翻译：可治疗性皮肤病综合征的治疗药物
公开(公告)号：US20100267796A1
公开(公告)日：2010-10-21
申请号：US12065120
申请日：2007-10-26
申请人： Tsuyoshi Yamagata , Kenji Shibata , Yoichi Nishiya , Takashi Seishi , Takashi Sakuma
发明人： Tsuyoshi Yamagata , Kenji Shibata , Yoichi Nishiya , Takashi Seishi , Takashi Sakuma
IPC分类号： A61K31/38 , C07D495/04 , A61K31/4155 , A61K31/381 , A61P1/00 , A61P1/12 , A61P1/14
CPC分类号： A61K31/38 , A61K31/381 , A61K31/4155 , C07D495/04
摘要： The present invention provides a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a compound having an adenosine uptake inhibitory activity, a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a tricyclic compound represented by formula (I) [wherein L represents —NHC(═O)— or the like, R1 represents a hydrogen atom, halogen, or the like, X1—X2—X3 represents S—CR7═CR8 (wherein R7 and R8 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like), or the like, Y represents —CH2SO2—, —SO2CH2— or the like, R2 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, or the like] or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译：本发明提供一种肠易激综合征治疗剂，其包含作为活性成分的具有腺苷摄取抑制活性的化合物，用于肠易激综合征的治疗剂，其包含作为活性成分的由式（3）表示的三环化合物 I）[其中L表示-NHC（= O） - 等，R 1表示氢原子，卤素等，X 1 -X 2 -X 3表示S-CR 7 = CR 8（其中R 7和R 8可以相同或不同，各自表示氢原子，卤素，取代或未取代的低级烷基等）等，Y表示-CH 2 SO 2 - ， - SO 2 CH 2 - 等，R 2表示取代或未取代的低级烷基，取代或未取代的低级烷氧基，取代或未取代的芳基等）或其药学上可接受的盐等。

6. 发明授权

US07354949B2 Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia 失效
公开(公告)号：US07354949B2
公开(公告)日：2008-04-08
申请号：US10472148
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
IPC分类号： A61K31/38 , A61K31/44 , A61K31/42
CPC分类号： C07D495/04 , A61K31/55
摘要： The present invention provides a therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen; X1-X2-X3 represents CR5═CR6—CR7═CR8, N(O)m═CR6—CR7═CR8, CR5═CR6—N(O)m═CR8, CR5═CR6—CR7═N(O)m, CR5═CR6—O, CR5═CR6—S, O—CR7═CR8, S—CR7═CR8 or O—CR7═N; Y represents 13 CH2S—, —CH2SO—, —CH2SO2—, —CH2O—, —CH═CH—, —(CH2)p—, —SCH2—, —SOCH2—, —SO2CH2— or —OCH2—; and R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or a substituted or unsubstituted heteroalicyclic group] or a pharmaceutically acceptable salt thereof.

7. 发明授权

US06211227B1 Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US06211227B1
公开(公告)日：2001-04-03
申请号：US09417626
申请日：1999-10-14
申请人： Makoto Yoshida , Takashi Seishi , Shigeru Aono , Tsuyoshi Yamagata , Kaoru Atsuki , Toshiaki Kumazawa , Haruki Takai , Koji Suzuki , Akira Karasawa
发明人： Makoto Yoshida , Takashi Seishi , Shigeru Aono , Tsuyoshi Yamagata , Kaoru Atsuki , Toshiaki Kumazawa , Haruki Takai , Koji Suzuki , Akira Karasawa
IPC分类号： A61K3138
CPC分类号： C07D495/04 , C07D313/12 , C07D337/12
摘要： The present invention provides tricyclic compounds which are useful for the treatment of pollakiuria and urinary incontinence and which are represented by general formula (I): (wherein R1 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; X1—X2—X3 represents CR5═CR6—CR7═CR8 (wherein R5, R6, R7 and R8, which may be the same or different, each represents hydrogen, substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, etc.), N(O)m═CR5—CR6═CR7 (wherein R5, R6 and R7 have the same significances as defined above, and m represents 0 or 1), S—CR7═CR8 (wherein R7 and R8 have the same significances as defined above), etc.; and when R2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, a substituted or unsubstituted N-substituted heterocyclic group, (wherein n is 0 or 1; R3 and R4, which may be the same or different, each represents hydrogen, substituted or unsubstituted lower alkyl, trifluoromethyl, etc., or R3 and R4 may be combined together to form cyclic alkyl; and Q represents hydroxy, halogen, etc.), etc., Y represents —CH2SO2—, —SCH2—, —SOCH2—, —SO2CH2—, etc.) and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供可用于治疗尿频和尿失禁的三环化合物，其由通式（I）表示：其中R 1表示氢，取代或未取代的低级烷基等; X 1 -X 2 -X 3表示CR 5 = CR6-CR7 = CR8（其中R5，R6，R7和R8可以相同或不同，各自表示氢，取代或未取代的低级烷基，羟基，取代或未取代的低级烷氧基等），N（O）m = CR5-CR6 = CR7（其中R5，R6和R7具有与上述相同的含义，m表示0或1），S-CR 7 = CR 8（其中R 7和R 8具有与上述相同的含义）等 ;当R 2表示氢时，取代或未取代的低级烷基，取代或未取代的低级烷氧基，取代或未取代的N-取代的杂环基，（其中n为0或1; R 3和R 4各自可相同或不同）代表氢，取代或未取代的低级烷基，三氟甲基脲基甲基等，或者R 3和R 4可以组合在一起形成环烷基; 和Q表示羟基，卤素等）等，Y表示-CH 2 SO 2 - ， - CH 2 - ， - SOCH 2 - ， - SO 2 CH 2 - 等）及其药学上可接受的盐。

8. 发明授权

US07276532B2 Remedies for vesical hyperactivity 失效
标题翻译：用于膀胱活动过度的补救措施
公开(公告)号：US07276532B2
公开(公告)日：2007-10-02
申请号：US10472143
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
IPC分类号： A61K31/38
CPC分类号： C07D495/04 , A61K31/55 , C07D337/12
摘要： The present invention provides a therapeutic agent for overactive bladder comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X1—X2—X3 represents CR5═CR6—CR7═CR8, CR5═CR6—S, and the like; Y represents —CH2S—, —SOCH2—, and the like; and R2 represents a hydrogen atom, and the like] or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供一种活性过氧化物的治疗剂，其包含作为活性成分的由式（I）表示的三环化合物：其中R 1表示氢原子，取代或未取代的低级烷基，和类似; X 1 - 2 - - - - - - - - - - - - - - - - - - （3） CR 7 -CR 8，CR 5 -CR 6 -S等; Y表示-CH 2 -S-，-SOCH 2 - 等; 和R 2表示氢原子等]或其药学上可接受的盐。

9. 发明申请

US20060276531A1 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia 审中-公开
标题翻译：代理治疗膀胱刺激症状伴有良性前列腺增生
公开(公告)号：US20060276531A1
公开(公告)日：2006-12-07
申请号：US11503067
申请日：2006-08-14
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William de Groat , Naoki Yoshimura , Adrian Sculptoreanu
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa , William de Groat , Naoki Yoshimura , Adrian Sculptoreanu
IPC分类号： A61K31/381
CPC分类号： A61K31/55 , A61K31/38 , A61K31/44
摘要： The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.
摘要翻译：本发明提供了一种用于治疗伴有良性前列腺增生的膀胱刺激症状的药剂，其包含作为活性成分的具有缓慢失活的A型K + / O通道开放活性的化合物或以及用于治疗伴有良性前列腺增生的膀胱刺激症状的筛选剂的方法，包括测量缓慢失活的A型K +通道开放活性作为指标。

10. 发明申请

US20060148885A1 Medicinal composition 审中-公开
标题翻译：药用成分
公开(公告)号：US20060148885A1
公开(公告)日：2006-07-06
申请号：US10562634
申请日：2004-07-16
申请人： Tsuyoshi Yamagata , Shiro Shirakura
发明人： Tsuyoshi Yamagata , Shiro Shirakura
IPC分类号： A61K31/38 , A61K31/381
CPC分类号： A61K45/06 , A61K31/38 , A61K2300/00
摘要： The present invention provides a pharmaceutical composition which is useful in the treatment for bladder irritative symptoms accompanied by benign prostatic hyperplasia and the like, and comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof, and an α1-adrenoceptor antagonist.
摘要翻译：本发明提供了可用于治疗伴有良性前列腺增生等的膀胱刺激症状的药物组合物，并且包含3,3,3-三氟-2-羟基-2-甲基-N-（5,5 ，10-三氧代-4,10-二氢噻吩并[3,2-c] [1]苯并噻吖庚因-9-基）丙酰胺或其药学上可接受的盐和α1 - 肾上腺素能受体拮抗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式